孟鲁司特钠对慢阻肺患者抗氧化能力与胶原指标表达的影响研究
2019-01-16杨建明
杨建明


【摘要】 目的:探討孟鲁司特钠对慢性阻塞性肺疾病(COPD)患者抗氧化能力和胶原指标表达的影响。方法:将本院收治的132例COPD患者随机分为治疗组67例,对照组65例,两组患者给予盐酸氨溴索片、噻托溴铵粉雾剂和布地奈德吸入剂常规治疗,治疗组在此基础上加用孟鲁司特钠。治疗3个月后,比较两组患者FEV1、FEV1%、FEV1/FVC,治疗前后血清中MDA、GSH、SOD含量变化以及血清中Ⅲ型前胶原(PCⅢ)、透明质酸(HA)含量水平。结果:治疗前,两组患者FEV1、FEV1%、FEV1/FVC比较,差异均无统计学意义(P>0.05);治疗后,治疗组患者FEV1(2.0±0.3)L、FEV1(67.8±11.6)%、FEV1/FVC(63.5±7.7)%,均显著高于对照组患者(P<0.05)。治疗3个月后,治疗组患者血清中含量MDA(6.1±1.0)nmol/L显著低于对照组患者(P<0.05),GSH(254.7±30.2)mg/L、SOD(57.9±6.2)U/mL显著高于对照组患者(P<0.05);治疗组患者血清中PCⅢ(62.3±12.9)μg/L,HA(120.0±21.0)ng/mL,均显著低于对照组患者(P<0.05)。结论:孟鲁司特钠能显著提高COPD患者的抗氧化能力,下调血清中胶原指标表达,减轻患者肺纤维化程度。
【关键词】 慢性阻塞性肺疾病; 孟鲁司特钠; 抗氧化; Ⅲ型前胶原; 透明质酸
Effect of Montelukast Sodium on Antioxidant Capacity and Expression of Collagen Markers in Patients with Chronic Obstructive Pulmonary Disease/YANG Jianming.//Medical Innovation of China,2019,16(25):00-012
【Abstract】 Objective:To investigate the effects of Montelukast Sodium on the expression of antioxidant capacity and collagen in patients with chronic obstructive pulmonary disease(COPD).Method:The 132 COPD patients admitted to our hospital were randomly divided into 67 cases in the treatment group and 65 cases in the control group.They were given regular treatment with Ambroxol Hydrochloride Tablets,Tiopromonium Powder Aerosols and Budesonide Inhalants.The treatment group added Montelukast Sodium.After 3 months of treatment,the levels of FEV1,FEV1%,FEV1/FVC,the serum MDA,GSH,and SOD levels before and after treatment,as well as the levels of PCⅢ(type Ⅲ precollagen)and HA(hyaluronic acid)of two groups in the serum were compared.Result:Before treatment,the two groups of patients FEV1,FEV1%,FEV1/FVC were compared,the difference was not statistically significant(P>0.05).After treatment,the treatment group patients FEV1(2.0±0.3)L,FEV1(67.8±11.6)%,and FEV1/FVC(63.5±7.7)% were significantly higher than those of the control group patients(P<0.05).After 3 months of treatment,the serum content of MDA(6.1±1.0)nmol/L
in the treatment group was significantly lower than that of the control group(P<0.05);GSH(254.7±30.2)mg/L,
SOD(57.9±6.2)U/mL,significantly higher than those of the control group(P<0.05).The serum of PCⅢ(62.3±12.9)μg/L,HA(120.0±21.0)ng/mL in the treatment group were significantly lower than those of the control group(P<0.05).Conclusion:Montelukast Sodium can significantly improve the antioxidant ability of COPD patients,lower the expression of collagen in serum,and reduce the degree of pulmonary fibrosis in patients.
【Key words】 Chronic obstructive pulmonary disease; Montelukast Sodium; Antioxidant; Type Ⅲ anterior collagen; Hyaluronic acid
First-authors address:The First Peoples Hospital of Wuxue,Wuxue 435400,China
doi:10.3969/j.issn.1674-4985.2019.25.003
慢性阻塞性肺疾病(chronic obstructive pulmoriary disease,COPD)简称慢阻肺,以慢性咳嗽,呼吸困难等气流受限为临床特征,呈进行性发展,后期可诱发慢性呼吸衰竭,自发性气胸或肺源性心脏病,导致患者致残甚至致死[1-2]。慢阻肺的病因及发病机制上不十分明确,目前认为氧化应激、职业粉尘、化学物质以及抽烟、感染等与慢阻肺病变呈正性相关[3-4]。研究表明,COPD肺间质纤维化时血清中胶原指标如Ⅲ型前胶原(PCⅢ)、透明质酸(HA)表现为升高。本研究针对孟鲁司特钠治疗的COPD患者时对抗氧化和胶原指标表达的影响,现将研究结果报道如下。
1 资料与方法
1.1 一般资料 选择2017年5月-2018年6月本科收治的132例COPD患者,所有患者符合COPD诊断标准[5],排出伴有严重肝肾功能障碍和近3个月内接受过同类药物临床试验者。将上述患者随机分为治疗组67例和对照組65例。
1.2 方法 所有患者均给予常规治疗,口……
